Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M306111200 on July 24, 2003

J. Biol. Chem., Vol. 278, Issue 41, 39461-39469, October 10, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/41/39461    most recent
M306111200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chawla-Sarkar, M.
Right arrow Articles by Lindner, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chawla-Sarkar, M.
Right arrow Articles by Lindner, D. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Suppression of NF-{kappa}B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL*

Mamta Chawla-Sarkar {ddagger} §, Joseph A. Bauer {ddagger} §, Joseph A. Lupica ¶, Bei H. Morrison {ddagger}, Zhuo Tang {ddagger}, Rhonda K. Oates {ddagger}, Alex Almasan ¶, Joseph A. DiDonato ¶, Ernest C. Borden {ddagger} ¶ and Daniel J. Lindner {ddagger} ¶ ||

From the {ddagger}Taussig Cancer Center, Center for Cancer Drug Discovery and Development and the Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an analog of vitamin B12 that delivers nitric oxide (NO) and increases the expression of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors. The specific aim of this study was to examine whether NO-Cbl could sensitize drug-resistant melanomas to Apo2L/TRAIL. Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by TUNEL and confirmed by examining levels and activity of key mediators of apoptosis. The activation status of NF-{kappa}B was established by assaying DNA binding, luciferase reporter activity, the phosphorylation status of I{kappa}B{alpha}, and in vitro IKK activity. NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts. Treatment with NO-Cbl followed by Apo2L/TRAIL induced apoptosis in Apo2L/TRAIL-resistant tumor cells, characterized by cleavage of caspase-3, caspase-8, and PARP. NO-Cbl inhibited IKK activation, characterized by decreased phosphorylation of I{kappa}B{alpha} and inhibition of NF-{kappa}B DNA binding activity. NO-Cbl suppressed Apo2L/TRAIL- and TNF-{alpha}-mediated activation of a transfected NF-{kappa}B-driven luciferase reporter. XIAP, an inhibitor of apoptosis, was inactivated by NO-Cbl. NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties of both agents and represents a promising anti-cancer combination.


Received for publication, June 10, 2003 , and in revised form, July 23, 2003.

* These studies were supported by the American Cancer Society, Ethicon Endosurgery, CCF Innovations, the Taussig Cancer Center Bridge Grant Program, and National Institutes of Health (to A. A.) Grants CA 81504 and CA 82858. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Both authors contributed equally to this work.

|| To whom correspondence should be addressed: 9500 Euclid Ave., R40 Cleveland, OH 44195. Tel.: 216-445-0548; Fax: 216-636-2498; E-mail: lindned{at}cc.ccf.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. E. Schade, G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Blood, February 1, 2008; 111(3): 1366 - 1377.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Baritaki, A. Katsman, D. Chatterjee, K. C. Yeung, D. A. Spandidos, and B. Bonavida
Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation
J. Immunol., October 15, 2007; 179(8): 5441 - 5453.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. W. Rahman, S. Ali, A. Aboukameel, S. H. Sarkar, Z. Wang, P. A. Philip, W. A. Sakr, and A. Raz
Inactivation of NF-{kappa}B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2757 - 2765.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Baritaki, S. Huerta-Yepez, T. Sakai, D. A. Spandidos, and B. Bonavida
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1
Mol. Cancer Ther., April 1, 2007; 6(4): 1387 - 1399.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka
Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells
Mol. Cancer Res., October 1, 2006; 4(10): 715 - 728.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Hu, C. Jiang, T. Schuster, G.-X. Li, P. T. Daniel, and J. Lu
Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
Mol. Cancer Ther., July 1, 2006; 5(7): 1873 - 1882.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. M. McCarthy, K. A. DiVito, M. Sznol, D. Kovacs, R. Halaban, A. J. Berger, K. T. Flaherty, R. L. Camp, R. Lazova, D. L. Rimm, et al.
Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma.
Clin. Cancer Res., June 15, 2006; 12(12): 3856 - 3863.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. M. Kim, J. J. Song, J. Y. An, Y. T. Kwon, and Y. J. Lee
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression
J. Biol. Chem., December 9, 2005; 280(49): 41047 - 41056.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Li, F. Ahmed, S. Ali, P. A. Philip, O. Kucuk, and F. H. Sarkar
Inactivation of Nuclear Factor {kappa}B by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer Cells
Cancer Res., August 1, 2005; 65(15): 6934 - 6942.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. S. Kim, I. Chang, J. Y. Kim, K.-H. Choi, and M.-S. Lee
Caspase-Mediated p65 Cleavage Promotes TRAIL-Induced Apoptosis
Cancer Res., July 15, 2005; 65(14): 6111 - 6119.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Okhrimenko, W. Lu, C. Xiang, D. Ju, P. M. Blumberg, R. Gomel, G. Kazimirsky, and C. Brodie
Roles of Tyrosine Phosphorylation and Cleavage of Protein Kinase C{delta} in Its Protective Effect Against Tumor Necrosis Factor-related Apoptosis Inducing Ligand-induced Apoptosis
J. Biol. Chem., June 24, 2005; 280(25): 23643 - 23652.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
F. H. Sarkar and Y. Li
Indole-3-Carbinol and Prostate Cancer
J. Nutr., December 1, 2004; 134(12): 3493S - 3498S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Zhang, T.-G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi
Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer
Cancer Res., October 1, 2004; 64(19): 7086 - 7091.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M. Whitmore, M. J. DeVeer, A. Edling, R. K. Oates, B. Simons, D. Lindner, and B. R. G. Williams
Synergistic Activation of Innate Immunity by Double-Stranded RNA and CpG DNA Promotes Enhanced Antitumor Activity
Cancer Res., August 15, 2004; 64(16): 5850 - 5860.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-T. Lin, C.-C. Chang, S.-T. Chen, H.-L. Chang, J.-L. Su, Y.-P. Chau, and M.-L. Kuo
Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-{kappa}B-dependent XIAP Up-Regulation
J. Biol. Chem., June 4, 2004; 279(23): 24015 - 24023.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement